Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
By A. Kornbluth, D. Sachar. American Journal of Gastroenterology, 2010
1,782 citations recorded by the source corpus.
Subfields: Economics and Econometrics, Epidemiology, Oncology
View Paper: https://www.semanticscholar.org/paper/f715b3601167b066de5e2535c8093d5b51da117a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Oncology
Citations in the corpus
- Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. (2012, neutral): “of patients (%)‡ 4 (8) 1 (3) 1 (3) 2 (6) 2 (4) 0.”
- Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. (2014, background): “1 AE 41 (52) AEs leading to discontinuation 6 (8) Serious AEs 6 (8) AEs in 5% of any treatment group Abdominal pain 4 (5) Abdominal pain, upper 4 (5) Anemia 4 (5) Fatigue 4 (5) Headache 8 (10) Nausea 10 (13) Pyrexia 3 (4) Vomiting 6 (8) AEs of interest Hepatobiliary events 13 (16) Infusion-related r”
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017, background): “In the OCTAVE Sustain trial, nonmelanoma skin cancers occurred in 4 patients: 3 patients in the 10-mg tofacitinib group who had a history of nonmelanoma skin cancer received a diagnosis of squamous-cell carcinoma (2) or basal-cell carcinoma (1), and 1 patient in the placebo group received a diagnosi”
- 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (2019, neutral): “Infliximab, adalimumab, and certolizumab are approved for the treatment of Crohn’s disease, and infliximab, adalimumab, and golimumab are approved for the treatment of ulcerative colitis, while etanercept is not approved for either condition (42,43).”